Pfizer Secures Metsera in a $10 Billion Acquisition

Pfizer has successfully finalized a $10 billion agreement to acquire Metsera, an innovative obesity drug developer, concluding a fierce competition with Novo Nordisk that captivated the pharmaceutical landscape this week.

The renowned New York pharmaceutical firm will offer $86.25 per share in cash, which consists of an initial payment of $65.60 along with a contingent value right of up to $20.65 per share based on future achievements. This proposal denotes a 3.69% premium compared to Metsera’s closing stock price last Friday.

This acquisition signifies a pivotal strategy for Pfizer, as the company seeks greater influence within the rapidly expanding market for weight-loss medications, largely dominated by Novo Nordisk and Eli Lilly. Past attempts by Pfizer to develop effective obesity therapies had not succeeded, thus rendering Metsera's valuable drug prospects a prime target.

Metsera boasts significant experimental drugs, including MET-097i, a GLP-1 injectable, and MET-233i, an amylin-mimicking compound, which are projected to offer joint peak sales nearing $5 billion, as per analysts. Both candidates aim to tap metabolic pathways akin to those driving the success of Wegovy and Mounjaro, the blockbuster offerings from Novo and Lilly.

Novo Nordisk, which previously attempted a last-minute counteroffer to regain its footing in the obesity drug arena, has now been surpassed. Metsera’s board mentioned that Novo’s proposal involved “unacceptably high legal and regulatory risks,” thereby favoring Pfizer’s more transparent cash-based bid.

The acquisition surged sharply from Pfizer’s initial $7.3 billion proposal made in September, highlighting the intensifying competition for promising obesity treatments. By completing this deal, Pfizer is placing significant bets on Metsera’s innovations to help reestablish itself in one of the pharmaceutical sector's most lucrative markets, expected to surpass $100 billion worldwide by the decade's end.

While Metsera currently operates at a loss with its medications still in development phases, Pfizer’s robust financial capabilities and global presence could streamline their journey towards approval and market entry. The agreement is now set to be presented to Metsera’s shareholders for approval, marking a monumental step in biotech acquisitions this year.